Evidence map›Paper›PMID 38093958›Full record

ArticleFrontiers in endocrinology2023

Imaging for assessment of cancer treatment response to immune checkpoint inhibitors can be complementary in identifying hypophysitis.

Anna Galligan, Amir Iravani, Arian Lasocki, Roslyn Wallace, Alison M Weppler, Nirupa Sachithanandan, Cherie Chiang, Peter G Colman, John Wentworth, Lavinia Spain and 6 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 6 citations in OpenAlex.

  1. Beyond MRI: Unveiling metabolic signatures of primary hypophysitis withJournal of endocrinological investigation · 2026
    Article
  2. Immune-Mediated Hypophysitis: An Updated Review.Journal of clinical medicine · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Anna Galligan *Immunology and Diabetes Unit, St Vincent's Institute of Medical Research, Melbourne, VIC, Australia.
Amir Iravani *Department of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Arian LasockiDepartment of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Roslyn WallaceDepartment of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Alison M WepplerDepartment of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Nirupa SachithanandanDepartment of Endocrinology and Diabetes, St Vincent's Hospital, Melbourne, VIC, Australia.
Cherie ChiangDepartment of Medicine, The University of Melbourne, Melbourne, VIC, Australia.
Peter G ColmanDepartment of Medicine, The University of Melbourne, Melbourne, VIC, Australia.
John WentworthDepartment of Medicine, The University of Melbourne, Melbourne, VIC, Australia.
Lavinia SpainDepartment of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
George Au-YeungThe Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia.
Belinda LeeDepartment of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Thomas W H KayImmunology and Diabetes Unit, St Vincent's Institute of Medical Research, Melbourne, VIC, Australia.
Rodney J HicksDepartment of Medicine, The University of Melbourne, Melbourne, VIC, Australia.
Shahneen Sandhu *The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia.
Balasubramanian Krishnamurthy *Immunology and Diabetes Unit, St Vincent's Institute of Medical Research, Melbourne, VIC, Australia.
Peter MacCallum Cancer Centre · AUUniversity of Melbourne · AUSt Vincent's Hospital · AUThe Royal Melbourne Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Hypophysitis is reported in 8.5%-14% of patients receiving combination immune checkpoint inhibition (cICI) but can be a diagnostic challenge. This study aimed to assess the role of routine diagnostic imaging performed during therapeutic monitoring of combination anti-CTLA-4/anti-PD-1 treatment in the identification of hypophysitis and the relationship of imaging findings to clinical diagnostic criteria. Methods: This retrospective cohort study identified patients treated with cICI between January 2016 and January 2019 at a quaternary melanoma service. Medical records were reviewed to identify patients with a documented diagnosis of hypophysitis based on clinical criteria. Available structural brain imaging with magnetic resonance imaging (MRI) or computed tomography (CT) of the brain and 2-deoxy-2-[ Results: There were 162 patients (median age 60 years, 30% female) included. A total of 100 and 134 had serial CT/MRI of the brain and FDG-PET/CT, respectively. There were 31 patients who had a documented diagnosis of hypophysitis and an additional 20 who had isolated pituitary imaging findings. The pituitary gland enlargement was mild, and the largest absolute gland size was 13 mm, with a relative increase of 7 mm from baseline. There were no cases of optic chiasm compression. Pituitary enlargement and increased FDG uptake were universally transient. High-dose glucocorticoid treatment for concurrent irAEs prevented assessment of the pituitary-adrenal axis in 90% of patients with isolated imaging findings. Conclusion: Careful review of changes in pituitary characteristics on imaging performed for assessment of therapeutic response to iICI may lead to increased identification and more prompt management of cICI-induced hypophysitis.

Indexed as

HypophysitisNeoplasmsPituitary DiseasesFemaleFluorodeoxyglucose F18HumansImmune Checkpoint InhibitorsMaleMiddle AgedPositron Emission Tomography Computed TomographyRetrospective StudiesFluorodeoxyglucose F18Immune Checkpoint Inhibitorscancer imagingcombination immune checkpoint inhibitionhypophysitisimmune related adverse eventsimmunotherapypituitary gland

Identifiers

PMID38093958
PMCPMC10716424
OpenAlexW4389149409

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.